| Literature DB >> 25106448 |
Hongcheng Lv, Yang Shi, Li Zhang, Dan Zhang, Guang Liu, Zhengduo Yang, Yan Li, Fei Fei, Shiwu Zhang1.
Abstract
BACKGROUND: We previously reported that polyploid giant cancer cells (PGCCs) exhibit cancer stem cell properties and express cell cycle-related proteins. HEY PGCCs induced by cobalt chloride generated daughter cells and the daughter cells had a strong migratory and invasive ability. This study is to compare the expression of cyclin E, S-phase kinase-associated protein 2 (SKP2), and stathmin between PGCCs with budding and control HEY cells, and determine the clinicopathological significance of cell cycle-related protein expression in ovarian tumors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25106448 PMCID: PMC4137091 DOI: 10.1186/1471-2407-14-576
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1PGCCs with budding daughter cells. A. HEY PGCCs and control HEY cells. a. Control HEY cells (×400). b. HEY PGCCs induced by treatment with 450 μM of CoCl2 for 48 h (small black arrow heads PGCCs; large black arrow heads budded daughter cells from PGCC; ×400). c. PGCCs generated daughter cells via budding (black arrow heads budded daughter cells from PGCC; ×100). d. PGCCs use budding for renewal and fast reproduction. Cells in panel 1A-c were cultured in complete medium for 8 h (×100). B. Western blot of cyclin E and SKP2 expression in HEY PGCCs with budding and control HEY cells. C. ICC staining of stathmin in HEY PGCCs with budding and control HEY cells (×200).
Figure 2PGCCs in OSC. a. PGCCs in low-grade OSC (×200). b. PGCCs in high-grade OSC (×200). c. Single PGCC located in the invasive front of low-grade OSC (×200). d. Single PGCC located in the stroma of high-grade OSC (×200).
Profile of single stromal PGCCs and lymph node metastasis in ovarian tumors
| Lymph node metastasis | ||||
|---|---|---|---|---|
| Yes | No | |||
| Primary ovarian tumor with metastasis | Single stromal PGCCs | Yes | 18 | 0 |
| No | 3 | 0 | ||
| Primary ovarian tumor without metastasis | Single stromal PGCC | Yes | 0 | 6 |
| No | 0 | 20 | ||
| Borderline serous cystadenoma | Single stromal PGCC | Yes | 0 | 0 |
| No | 0 | 12 | ||
The differences of the percentage of tumor with single PGCC in the stroma
| Group | n | The percentage of tumor with single PGCC in the stroma |
|
| |
|---|---|---|---|---|---|
| Primary ovarian tumor with metastasis | I | 21 | 85.71% (18/21) | 18.240 | 0.000 |
| Primary ovarian tumor without metastasis | III | 26 | 23.08% (6/26) |
Figure 3The expression of SKP2, cyclin E, and stathmin in OSC. SKP2 expression in (a) borderline ovarian serous cystadenoma, (b) low-grade OSC, (c) high-grade OSC, and (d) metastatic foci (×200). Cyclin E expression in (e) borderline ovarian serous cystadenoma, (f) low-grade OSC, (g) high-grade OSC, and (h) metastatic foci (×200). Stathmin expression in (i) borderline ovarian serous cystadenoma, (j) low-grade OSC, (k) high-grade OSC, and (l) metastatic foci (×200).
The differences of stathmin, cyclin E and SKP-2 expression in the four groups of human ovarian tumors
| Group | n | SKP-2 | Cyclin E | Stathmin | |
|---|---|---|---|---|---|
| Primary ovarian tumor with metastasis | I | 21 | 1.33 ± 1.55 | 2.57 ± 2.13 | 0.86 ± 1.93 |
| Corresponding metastatic tumor | II | 21 | 1.95 ± 1.74 | 4.42 ± 1.98 | 1.95 ± 2.15 |
| Primary ovarian tumor without metastasis | III | 26 | 0.88 ± 0.99 | 2.38 ± 0.46 | 0.27 ± 0.87 |
| Borderline serous cystadenoma | IV | 12 | 0.17 ± 0.38 | 1.00 ± 1.27 | 0.17 ± 0.57 |
|
| 12.384 | 17.985 | 20.226 | ||
|
| 0.006 | 0.000 | 0.000 | ||
The differences of stathmin, cyclin E and SKP-2 expression in primary ovarian tumor and their corresponding metastatic tumor
| Group | n | SKP-2 | Cyclin E | Stathmin | |
|---|---|---|---|---|---|
| Primary ovarian tumor with metastasis | I | 21 | 1.33 ± 1.55 | 2.57 ± 2.13 | 0.86 ± 1.93 |
| Corresponding metastatic tumor | II | 21 | 1.95 ± 1.74 | 4.42 ± 1.98 | 1.95 ± 2.15 |
| Z | -1.182 | -2.670 | -2.487 | ||
|
| 0.237 | 0.008 | 0.013 | ||
The differences of stathmin, cyclin E and SKP-2 expression in primary ovarian tumor without metastasis and borderline serous cystadenoma
| Group | n | SKP-2 | Cyclin E | Stathmin | |
|---|---|---|---|---|---|
| Primary ovarian tumor without metastasis | III | 26 | 0.88 ± 0.99 | 2.38 ± 0.46 | 0.27 ± 0.87 |
| Borderline serous cystadenoma | IV | 12 | 0.17 ± 0.38 | 1.00 ± 1.27 | 0.17 ± 0.57 |
|
| -2.450 | -2.068 | -0.295 | ||
|
| 0.014 | 0.039 | 0.768 |